Immunogens for HIV vaccination

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10815278
APP PUB NO 20180170971A1
SERIAL NO

15718635

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to novel immunogens based on overlapping peptides (OLPs) and peptides derived therefrom useful for the prevention and treatment of AIDS and its related opportunistic diseases. The invention also relates to isolated nucleic acids, vectors and host cells expressing these immunogens as well as vaccines including said immunogens.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
CORPORACIÓN QUÍMICO-FARMACÉUTICA ESTEVE S APASSEIG DE LA ZONA FRANCA 109 4ª PLANTA BARCELONA 08038

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Brander, Christian Tiana, ES 10 34
Llano, Anuska Castellar del Valles, ES 4 22
Mothe, Pujadas Beatriz Barcelona, ES 7 28

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Apr 27, 2028
11.5 Year Payment $7400.00 $3700.00 $1850.00 Apr 27, 2032
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00